Integrative radiopathomics model for predicting progression-free survival in patients with ...
NPC patients were treated based on stage, with radiotherapy alone for stages I–II, and concurrent chemoradiotherapy (CCRT) for stages II–IVA, combined with adjuvant or induction chemotherapy. Follow-ups included MRI at varying intervals, with progression-free survival (PFS) as the primary endpoint. MRI protocols used a 1.5-Tesla scanner with specific T1WI, T2WI, and CET1-w settings. Radiomics signature construction involved preprocessing, segmentation by radiologists, feature extraction, and selection using mRMR and LASSO methods. Pathomics signature used a Swin Transformer to extract features from H&E-stained slides. A radiopathomics model was built integrating radiomics, pathomics signatures, and clinical factors, evaluated by C-index and calibration curve.
Highlighted Terms
Related News
NPC patients were treated based on stage, with radiotherapy alone for stages I–II, and concurrent chemoradiotherapy (CCRT) for stages II–IVA, combined with adjuvant or induction chemotherapy. Follow-ups included MRI at varying intervals, with progression-free survival (PFS) as the primary endpoint. MRI protocols used a 1.5-Tesla scanner with specific T1WI, T2WI, and CET1-w settings. Radiomics signature construction involved preprocessing, segmentation by radiologists, feature extraction, and selection using mRMR and LASSO methods. Pathomics signature used a Swin Transformer to extract features from H&E-stained slides. A radiopathomics model was built integrating radiomics, pathomics signatures, and clinical factors, evaluated by C-index and calibration curve.